Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia.

Bezafibrate is safe and effective for long-term management of canine hypertriglyceridemia.

This retrospective study evaluated the long-term safety and efficacy of oral bezafibrate in 55 client-owned dogs with hypertriglyceridemia. Dogs were treated with bezafibrate at a median dose of 5.5 mg/kg once daily and stratified into three groups: primary hypertriglyceridemia (n=group 1), secondary hypertriglyceridemia without concurrent treatment changes (n=group 2a), and secondary hypertriglyceridemia with concurrent treatment changes (n=group 2b). Serum triglyceride concentrations, creatine kinase, and alanine aminotransferase activities were monitored at baseline and follow-up intervals up to 18+ months. All groups demonstrated significant triglyceride reduction (P<0.01), with a median decrease of 85% across the study period. No significant differences in final triglyceride concentrations were observed between groups (P=0.13). Adequate treatment response (≥50% triglyceride reduction) was achieved in the majority of dogs. Adverse effects possibly attributable to bezafibrate were noted in only 4/55 dogs, primarily gastrointestinal or hepatic in nature. The findings support long-term bezafibrate use as a safe and effective treatment option for managing both primary and secondary hypertriglyceridemia in dogs.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.